Cheelcare’s reimbursement-led mobility platform offers asymmetric upside, but its $39.1 million valuation requires rapid manufacturing scale-up, Curio approval, and conversion of bookings into profitable revenue.
Overview
Cheelcare Inc. (CHER.V) is a Canadian medical-device and assistive-technology company addressing mobility limitations through the Companion front-mounted power assist, Curio robotic power wheelchair, and AWARE rear-view safety system. Its moat combines patented hardware, PDAC verification under HCPCS E0986, clinical switching costs, and a distribution network exceeding 500 dealers. Q3 fiscal 2026 gross revenue rose 16.0% to $549,857, net revenue reached $470,614, and gross margin expanded to 44.3% from 31.2%, although operating expenses increased 75.0% to $777,108 and the company remained loss-making. **The key inflection is reimbursement-led U.S. commercialization:** Medicare and Medicaid access allows dealers to prescribe and bill the Companion more broadly, while Curio’s expected FDA 510(k) clearance and Ontario ADP listing could add a premium product engine. **The opportunity is highly asymmetric but execution-dependent.** April 2026 bookings grew 147% year over year, and a July 3, 2026 financing raised $3.02 million, supporting liquidity. At $1.72, the company has a $39.10 million market capitalization but trades at approximately 19.55x trailing sales and 114.22x book value, making successful scaling essential.